Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IM Cannabis Corp C.IMCC

Alternate Symbol(s):  IMCC

IM Cannabis Corp. is a Canada-based medical cannabis company. The Company operates in Israel through its commercial relationship with Focus Medical Herbs Ltd. (Focus Medical), which has a cultivation license to breed, grow and supply medical cannabis products in Israel. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centres and logistical hubs in Israel. The Company operates through Adjupharm GmbH in Europe, which is a medical cannabis producer and distributor with wholesale, narcotics handling, manufacturing, procurement, storage, and distribution licenses granted by German regulatory authorities that allow for import/export capability with requisite permits. The Company operates through Trichome and its subsidiaries Trichome JWC Acquisition Corp. and MYM Nutraceuticals Inc., where it cultivates and processes cannabis for the adult-use market at its Ontario and Nova Scotia facilities under the WAGNERS and Highland Grow brands.


CSE:IMCC - Post by User

Bullboard Posts
Post by LatAmBullon Feb 21, 2020 11:01am
231 Views
Post# 30717714

Cormark Initiating Coverage Report

Cormark Initiating Coverage ReportCormark Securities initiates with a Buy Rating and a $0.70 target price.

A few highlights from the report: 
  • Company currently has $16 million in cash and no debt (current implied enterprise value of ~$37 million)
  • This compares to a discounted cash flow value of ~$83 million ($102 million equity value including cash) despite using conservative assumptions of a 15% discount rate and 8.5% growth rate
  • 8.5% growth rate feels conservative given the scope of opportunity for EU expansion highlighted by the report
  • FY 2020 revenue of ~$31 million and positive EBITDA of ~$2 million
Pretty impressive for IMCC that Cormark was able to come out with such a great report during such a period of overall uncertainty. I sense that there is a lot of room for upwards revisions - assumptions feel very conservative, which makes sense given the credibility of the institution that wrote the report.


Bullboard Posts